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Summary 
The mechanisms by which cellular immunity maintains  the asymptomatic state after human 
immunodeficiency virus type 1 (HIV-1) infection are poorly understood. CD4 + T  lymphocytes 
play a complex role in regulating anti-HIV effector pathways, including activation of macrophages, 
which are themselves implicated in clinical  latency and pathogenesis of symptomatic acquired 
immune deficiency syndrome. We have found that a newly identified T helper type 2 lymphokine, 
interleukin 13 (IL-13), inhibits HIV-I~^ and B~-L replication in primary tissue culture-derived 
macrophages but not in peripheral blood lymphocytes. Viral production in cells was measured 
by viral protein (p24) and reverse transcriptase levels, while entry was assessed by proviral DNA 
analysis at timed intervals after infection. Inhibition by IL-13 was dose and time dependent and 
not mediated through altered viral entry, reverse transcription,  or viral release. IL-13 is therefore 
a candidate cytokine for the suppression of HIV infection within monocytes and macrophages in vivo. 
M 
acrophages as well as T lymphocytes play a central role 
during the pathogenesis of AIDS (1-5). During asymp- 
tomatic AIDS infected circulating  cells of both types have 
been shown to harbor unexpressed HIV in vivo (6), while 
virus is continually being produced within lymph nodes (7, 
8). The mechanisms that regulate HIV expression during the 
different stages of disease are not well understood. Cytokines, 
while regulating immune responses, may influence viral ex- 
pression in vivo, since studies in vitro have shown clear effects 
upon HIV replication  (9). 
IL-13,  a recently characterized  human  lymphokine pro- 
duced by activated T cells, displays immunomodulatory effects 
on B cells and macrophages. This new cytokine is a member 
of the IL-4 superfamily and shares  Th-2  type activities on 
macrophages with IL-4 and IL-10, even though its described 
synergy with IL-2 in IFN-3~ release by NK cells suggests its 
activity is not restricted to a generalized shutdown of Th-1 
responses (10). Therefore, the present study of IL-13 and its 
effect on HIV replication in T  cells and macrophages is of 
interest in understanding the possible mechanisms that regu- 
late HIV replication  during the different stages of AIDS patho- 
genesis.  We show that  human  (h)rlL-13  has an inhibitory 
effect on HIV replication in tissue culture-differentiated mac- 
rophages  (TCDM),  and not in T  cells. 
Different portions of this work were submitted in abstract form to the 
1993 Keystone  Symposia in Keystone, CO on Cytokines and Cytokine 
Receptors: From Cloning to the Clinic (January), and in Albuquerque, 
NM on Frontiers in HIV Pathogenesis (March). 
Materials and Methods 
Isolation and Culture of  Pe@heral  Monocytes  and Lymphocytes.  Total 
human PBMC were isolated from healthy donors as described (11); 
in short, FicoU-Hypaque-isohted mononuclear cells were incubated 
for 1 h in 2% gelatin-coated plates. Adherent cells (TCDM), >94% 
CD14 § by FACS  |  (Becton Dickinson  & Co., Mountain  View, 
CA), were cultivated in 5% of pooled human serum for 48 h be- 
fore transfer to either a 96-well plate at a density of 10  s cells/well 
(200/zl total volume), or to eight-chamber culture slides (177402; 
Nunc Inc., Naperville, IL) at a density of 2  x  10  s (400/~1 total 
volume). Nonadherent lymphoid cells (PBL) were stimulated with 
1 ~g/ml PHA-P (Wellcome Laboratories, Beckenham, Kent) for 
72 h in 20% FCS and subsequently maintained  with 10% FCS 
and 80 ng/ml IL-2 (Pharmacia, Uppsala, Sweden) in a 96-well plate 
at a density of 10  s cells/well (200/~1 total volume). 
HIV Strains.  Macrophage-tropic viral stocks HIV-I~A 0) and 
HIV-1B,.L (2) were  grown  and  titrated  in TCDM as described 
(11) to 1.9  x  10  s tissue culture infectious dose (TCID  s~ and 2.7 
x  104 TCID  s~ respectively. T cell-tropic viral stock HIV-lm (12) 
was grown in  C8166 cells and  titrated  in  PBL  to 4.4  x  104 
TCID  s0. 
Cytokine Treatment  and HIV Infection of Target Cells.  IL-13  was 
provided by Sanofi-Elf as supernatant from COS-transfected  cells 
(COS Ib13) and as purified recombinant protein from CHO cells 
(hrIb13). 
hrIL-13 titration  studies were performed in triplicate cultures 
of TCDM and PBL from the same donor with decreasing concen- 
trations of hrIL-13 (<30 pg endotoxin/#g of protein) starting from 
250 ng/ml. The cytokine was added to cultures for 72 h, leaving 
an equal portion of untreated cells for postinfection treatment  and 
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Figure  1.  hrlL-13  inhibits HIV-1 replication in TCDM but not PBL. 
(A) Coulter  TM ELISA: p24 antigen levels (intracellular [IC] and extracel- 
lular [EC]) at 11 d postinfection in TCDM treated with hrlL-D for 72 h 
before viral challenge (HIV-I~A [m.o.i., 0.12]). TCDM were plated at 
10  s cells per well; results are presented in nanograms per milliliter as the 
mean (_  SD) of triplicate assays. (B) In-house ELISA: p24 antigen EC 
levels (note scale) in corresponding PBL at 7 d postinfection under iden- 
tical conditions of infection (HIV-L~DA [m.o.i., 0.12]) and treatment as 
for TCDM. (C) In-house ELISA: p24 antigen EC levels in PBL 7 d after 
infection with HIV-lmB  (m.o.i. 0.03) under identical conditions to those 
shown in B. 
HIV-infected controls. HIV-I~A (multiplicity of infection [m.o.i], 
0.12) was added to TCDM, PBL, and respective control triplicate 
cultures, while HIV-1InB  (m.o.i., 0.03) was only added to PBL and 
its control triplicates.  Medium and hrlL-D were replenished every 
3 d until 7 d in PBL and 11 d in TCDM.  Culture supernatants 
and cell lysates prepared in 100/A 1% Empigen lysis buffer for I h 
at 60~  were stored at  -70~  before assay of extra- and intracel- 
lular p24 antigen. 
Growth curves of HIV-I~A (m.o.i., 0.04) and HIV-1B~-L  (m.o.i., 
0.02) in TCDM were performed in eight-chamber slides, hrIL-13 
(10 ng/ml) was added in duplicate 72 h before challenge with HIV-1 
or 18 h postinfection; the remaining chambers in each slide served 
as controls (hrIL-13, infected, uninfected). Medium and hrIb13 were 
replenished every 3 d. Supernatants were collected every 2 d and 
kept at  -70~  until tested. 
Proliferation Assays.  After cultivation of TCDM in microtiter 
plates for 24, 48, and 72 h, in the presence or absence of hrIL-13, 
[3H]thymidine was added (0.25 #Ci/well) and incubated  for a fur- 
ther 18 h. Triton X-100 was then added to a concentration of 0.25%o 
(vol/vol), released nuclei were harvested onto glass fiber falters using 
an automated harvester, and incorporated [3H]thymidine was mea- 
sured by liquid scintillation spectrometry (LS5000 CE; Beckman 
Instrs., Inc., Fullerton, CA). 
Virus Entry Assay by PCR.  TCDM were cultured in 96-well 
plates (10  s cells/well) and treated for 72 h with hrIL13 (10 ng/ml) 
before infection with HIV'IADA (m.o.i., 0.12). Cells were lysed at 
0, 2, 4, 8,  12,  16, and 20 h postinfection in a buffer containing 
100 mM KC1, 20 mM "Iris, pH 8.4, 500/zg/ml proteinase K, and 
0.2% (vol/vol) NP-40. PCR was performed on cell lysates as de- 
scribed (11), using a Programmable Thermal Controller (M.J. Re- 
search Inc., Watertown, MA). The PCR primer sequences for LTR, 
gag, and human B-globin gene (DNA control) were as follows. 
HIV-1  LTR primers:  U3(sense)  CACACAAGGCTACTTCCC- 
TGA;  U5(antisense)GATCTCTAGTTACCAGAGTCAC;  PCR 
product, 540 bp.  HIV-1 gag primers: gag (sense) GGTACATCA- 
GGCCATATCACC;  gag  (antisense)  GGTACATCAGGCCAT- 
ATCACC; PCR product, 627 bp. Human 3-globin control primers; 
glb (sense) CCTTTGTTCCCTAAGTCCAA; glb (antisense) CCT- 
CACCTTCTTTCATGGAG; PCR product, 238 bp. 
Detection of CD4 in TCDM.  TCDM were treated with hrIL-13 
(10  ng/ml)  and  assayed for CD4  expression by FACS  |  ADP 
318/C4120 mouse IgG1 mAb (MRC AIDS Directed Programme, 
London,  UK) was  used to detect CD4  on TCDM.  MOPC-21 
(Sigma,  Inc., Poole,  UK) mouse IgG1 was  used  as an isotype- 
matched Ab control and 15.2 mouse IgG1 against CD54 (provided 
by Dr. Nancy Hogg, Imperial Cancer Research Fund Labs., London, 
UK) as a positive control for antigen expression.  FITC-conjugated 
rabbit anti-mouse Ig (RAM-FITC) (Serotec Ltd., Oxford, UK) 
was  used to detect bound Ab. 
Reverse Transcriptase  Activity Assay.  5/zl of culture supernatants 
was added to 50/A of a mixture containing poly(A), oligo(dT) 
(Pharmacia  Fine  Chemicals,  Piscataway,  NJ),  MgC12, and  32p. 
labeled deoxythymidine 5'-triphosphate (dTTP) (Amersham Corp., 
Amersham, Buckinghamshire  , UK), and incubated for 1.5 h  at 
37~  3/zl of the mixture was  spotted in duplicate onto DE81 
paper, air dried, and washed four times in 2 x  SSC buffer and two 
additional times in 95% ethanol. The paper was then dried and 
either cut and assayed by scintillation counting or analyzed by pho- 
tophosphoimaging (Molecular Dynamics, Kent, UK). 
HIVELISA.  Supernatants were initially tested for p24 antigen 
by an in-house-adapted ELISA (13) as described (14). Macrophage- 
tropic viral supernatants  were further tested with  a Coulter  TM 
HIV-1p24  kit  (Luton,  Bedfordshire,  UK).  The  sensitivity  for 
macrophage-tropic strains between the two ELISAs differed by a 
factor of 100. 
Results  and Discussion 
We have defined a model system in which TCDM and cor- 
responding PBL from normal individual donors are challenged 
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graphs to illustrate the morphologic 
effects of hrlb13  in TCDM (9 d 
postinfi~on with HIV-1ADA  [m.o.i. 
0.12])  in  96-well  plates.  (A)  No 
cytokine,  (B)  1  ng/ml,  (C)  10 
ng/ml,  and  (D)  150  ng/ml.  A 
(arrows)  shows  examples of HIV- 
induced  syncytium  formation and 
cytolysis in TCDM. C shows hrlb 
13-dependent aggregation of viable 
macrophages (more pronounced in 
D, arrows)  and HIV c.p.e, protection, 
which are lost at 1 ng/ml II:13 (B). 
These pictures correspond to the ex- 
periment from which Fig. 1 A was 
derived (x 20). 
with a defined infectious challenge of different HIV-1 strains 
(ADA, Ba-L, and IIIB) that express different tropism for pri- 
mary macrophages and lymphocytes. Viral replication during 
the 2 wk after infection was measured by several indepen- 
dent assays: intra- and extracellular p24 antigen, reverse tran- 
scriptase, cytopathic effect (c.p.e.), and PCR analysis for pro- 
viral  DNA. 
The effect of IL-13 on HIV-1 replication was determined 
using a range of lymphokine concentrations added before, 
at the time of, or after challenging with virus at various m.o.i. 
In a series of eight initial independent experiments COS IL-13 
inhibited  viral  replication  of  both  HIV-I~A  and  B~-L- 
infected TCDM compared with COS control supernatants, 
while  not  affecting  PBL  infected with  HIV-lmB.  These 
studies with COS IL-13 showed characteristic  aggregation 
of TCDM when viewed by phase contrast microscopy, which 
correlated with the anti-HIV effect and was absent from con- 
trol supernatants (data  not shown). 
To confirm that the anti-HIV and morphological effects 
were due to IL-13,  purified recombinant protein was used 
to titrate both effects. 1-10 ng/ml hrIL-13 inhibited, up to 
30-fold, intra- and extracellular  p24 production in TCDM 
that had been pretreated with cytokine for 72 h before chal- 
lenge with HIV-I~A and then maintained in its presence 
(Fig. 1 A). The morphological  effects of hrlL-13 (Fig. 2) treat- 
ment  in  the  same  HIV-l~A-infected  cultures  resembled 
those observed with COS IL-13.  These micrographs illus- 
trate dose-dependent aggregation of TCDM treated with hrlL- 
13 and inhibition of virus-induced c.p.e., characterized by giant 
cell formation followed by membrane disruption and cytol- 
),sis. Control experiments confirmed that both activities were 
destroyed by heat inactivation (not shown). Uninfected TCDM 
remained fully viable at all hrlL-13 concentrations tested, and 
a similar concentration-dependent cell aggregation was ob- 
served. Indeed, at the same doses of hrlL-13, levels of man- 
nose receptor are increased on these cells (our unpublished 
observations), confirming a lack of cytotoxicity. Inhibition 
of p24 antigen production by hrlL-13 treatment 18 h postin- 
fection and maintained in its presence thereafter was com- 
parable to inhibition observed after hrlL-13 pretreatment in 
10 of 12 experiments. Two experiments showed no inhibi- 
Figure  3.  hri1:13  inhibits  HIV-1 ~verse  transcriptase  production in 
TCDM. Shown is a photophosphoimager  exposure of  DE81 paper spotted 
with 3/tl of extracellular supernatants derived from duplicate 16-d growth 
curves of HIV-lta~A  and HIV-I~.L in control and 10 ng/ml Ib13-treated 
(72 h pre-HIV infection)  TCDM. 
745  Montaner et al.  Brief Definitive  Report Figure 4.  hilL-13  does not inhibit viral entry into TCDM. Shown  is 
a time sequence  >20 h postinfection  by HIV-l^D^(m.o.i.  0.12). (A) Two 
double-loaded  2% agarose  gels with PCR products for HIV LTR (540 
bp) and human  B-globin  control  (238 bp) after  HIV infection  in untreated 
TCDM. (B) Similar  format  for TCDM pretreated  with 10 ng/ml hrlL-13 
72 h before HIV infection. 
tion when hrlL-13 treatment was delayed until after infec- 
tion. hrIL-13 HIV-1 inhibition in TCDM at 10 ng/ml was 
further confirmed with additional viral growth curves mea- 
suring supernatant reverse transcriptase (Fig.  3) and p24 an- 
tigen levels after infection with either HIV-I~^  or Ba-L. 
Analysis of cellular morphology of TCDM in the absence 
of virus showed that hrIL-13 at 10 ng/ml induced aggrega- 
tion and time-dependent formation of multinucleated giant 
cells, compared with background polykaryon levels with 5% 
human serum alone. IL-4 has also been reported to induce 
giant cell formation (15), corresponding to the apparent bio- 
logical similarities described between IL-4 and IL-13 (8). Fur- 
ther experiments are needed to establish the mechanism and 
efficacy of TCDM giant cell formation by hrlL-13, and its 
relationship to HIV-induced cell fusion and cytolysis. 
hrlL-13 did not inhibit HIV-1 replication in PBL under 
comparable conditions, with either the identical strain and 
m.o.i,  as  used  in  TCDM  (HIV-l^D^[m.o.i.,  0.12]),  or  a 
more infectious lymphotropic strain (HIV-111m[m.o.i., 0.03]) 
(Fig.  1, B and C, respectively). There was no inhibition of 
p24 antigen produced in either instance and no cytotoxicity 
resulting from hrlL-13 itself at all concentrations tested. These 
results were confirmed in two additional experiments. 
The possible mechanism by which hrlL-13 (10 ng/ml) in- 
hibited HIV-1 replication in TCDM was investigated. HrlL-13 
did not affect cell surface CD4 + or thymidine incorporation 
in uninfected cells (not shown). Viral entry and reverse tran- 
scription as measured by PCP, for viral LTR (Fig.  4) and 
gag primers (not shown) were similar in treated and untreated 
controls.  The HIV LTtL signal appeared simultaneously at 
8 h in both hrlL-13-treated and untreated TCDM. Proviral 
DNA remained detectable throughout the period of culture, 
and recovery  experiments (no replenishment of IL-13) showed 
that HIV had not been eradicated by IL-13 (not shown). Ex- 
periments such as those described above (Hg. 1 A) established 
that  IL-13  did not inhibit release  of virus p24  antigen by 
TCDM into the culture supernatants. Further experiments 
are needed to establish  the intracellular process between re- 
verse transcription and p24 translation by which IL-13 in- 
hibits HIV-1  production in TCDM. 
Only IFN-~x and IFN-/~ have been consistently reported 
to inhibit HIV-1 replication in macrophages or monocytoid 
cell lines, while other cytokines, including IFN-% IL-4, and 
TGF-/~,  are categorized "bifunctional" since they have been 
reported to enhance and/or inhibit HIV-1  (9,  16-18).  The 
factors responsible for the variable effects in studies concerning 
this latter group of cytokines have not been defined, other 
than  possible  differences in  monocyte culture  conditions, 
timing of cytokine addition, cytokine doses used, and donor 
variation. In the present study, variation in the efficiency of 
replication of HIV-I~a~^  and Ba-L in TCDM from different 
apparently healthy donors may partly account for the differ- 
ence in  inhibition  observed when hrlL-13  treatment  was 
delayed until after infection. 
IL-13 provides a potential pathway by which activated T 
lymphocytes can suppress  HIV replication in macrophages 
in vivo and inhibit  dissemination of monocytotropic vari- 
ants (19).  IL-13 may also contribute to the maintenance of 
postintegration HIV latency (8) by its inhibition of mono- 
cyte IL-6  and TNF-c~ production  (9).  IL-13  treatment in 
HIV + patients could have a beneficial virostatic action to re- 
duce the systemic viral load and be of use in combination 
with  other forms of antiviral therapy. Further studies  are 
needed to study its mechanism of action in vitro and the con- 
tribution of host IL-13 during different stages of the disease 
in vivo. 
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